Amlodipine: Mechanism-based CYP 3A4-inhibitor, probably of too low potency to be porphyrogenic. No significant inhibition or induction of CYP 3A4 is observed in clinical use. One publication reports an acute attack following the use of amlodipine, but there are 37 reports (per January 2010) of safe use in carriers of acute porphyria. Dyspeptic symptoms may cause potentially porphyrogenic reductions in food intake. Effect on PXR-activation by plasma calcium-deficit hypo-insulinemia can not be excluded, but are reported to be rare, and seemingly without clinical significance with regard to porphyrogenic ALAS1-induction. Olmesartan Medoxomil: Olmesartan is not metabolized by CYP, and no CYP interaction potential is observed in vitro nor anticipated.

Amlodipine: 3-Ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methylpyridine-3,5-dicarboxylate. M =408.9. Dihydropyridine derivative. Contains one cyclic tertiary amine group, shown in other drugs to cause irreversible or quasi-irreversible (nicardipine) inhibition (Ma, 2000; Hollenberg, 2008). Other cyclic tertiary amine MB-inhibitors have been shown to give rise to 2,3 dihydropyridinium metabolites, which bind to the CYP-apoprotein without loss of spectrally detectable heme (Hollenberg, 2008). Olmesartan Medoxomil: Angiotensin II receptor antagonist. In medicinal products for oral administration, it is available as the prodrug olmesartanmedoxemil.

Amlodipine: Amlodipine is a dihydropyridine calcium-channel blocker. It is used in the management of hypertension and angina pectoris. Amlodipine exerts its effect by relaxing arterial and arteriolar smooth muscle. The common side effects are nausea, acute abdominal pain, dyspepsia and dyspnoea. Less common side effects are insomnia, irritability, depressive mode, back-pain, myalgia, arthalgia, paraesthesia and peripheral neuropathy. Olmesartan Medoxomil: Olmesartan medoxomil is used in the treatment of essential hypertension.

Amlodipine: Possibly significant.

Amlodipine: Amlodipine is extensively metabolized in the liver by CYP 3A4. It is a substrate and only moderately potent (Ki=4.9 uM) inhibitor of CYP 3A4. It is not a substrate of P-Gp. Listed as irreversible CYP 3A4-inhibitor (kinact=0.35; Ki=2.6 uM; plasma concentration=0.1-0.4 uM. Partition ratio data not available)(Zhou, 2007). On CYP-oxidation the tertiary amine function undergoes N-dealkylation forming a reactive intermediate which attacks the heme-component of the enzyme (Hollenberg, 2008). The therapeutic plasma concentration of the drug in comparison to the relatively high concentration needed for half-maximal CYP 3A4- inhibition (Ki=2,6 uM)) makes it less likely for amlodipine to cause irrversible CYP-inhibition and heme-destruction of a degree to cause a significant ALAS1-induction. On the other hand it is used in long-term therapy, with a possible chronic low-intensive drain of hepatic heme. In clinical use, there are no observations of significant inibition or induction of CYP-metabolism of other drugs (Nishio, 2005; Meredith, 1992). Olmesartan Medoxomil: The prodrug olmesartan medoxomil is rapidly converted to the pharmacologically active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinal tract (SPC). Olmesartan is not further metabolized, and is excreted primarily via the bile (up to 90 per cent), and the rest by renal excretion (Yang 2016). Olmesartan had no clinically relevant inhibitory effects on in vitro human CYP 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4 (SPC).

Amlodipine: Although dihydropyridines such as nifedipine are highly porphyrinogenic in chick embryo liver cell cultures, amlodipine because of its basic amino side chain (pKa= 8.6) is water-soluble and less likely to be an inducer of ALA-synthase(Gorchein, 1997).

Amlodipine: C.Andersson 2004; 10 patient reports in carriers of AIP. S.Thunell 2004; 4 patient reports in carriers of AIP.

Amlodipine: Report of attack: Kepple, 1997. Reports of uneventful use: 1.Gorchein 1997. 2. Cinemre, 2007.

Amlodipine: Uneventful use reported in 63 patients with acute porphyria. Olmesartan Medoxomil: Uneventful use reported in 3 patients with acute porphyria.